Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session”In the company’s words, NCT00117936 on ClinicalTrials.gov
- Tested for
- Coronary Disease, Coronary Heart Disease, Myocardial Ischemia, Coronary Arteriosclerosis, Peripheral Arterial Disease, Stenosis, Intermittent Claudication
- Main trialPhase 2
- “Treatment for no-option heart patients with coronary artery disease. Procedure includes the injection into the heart of a protein growth factor, administered by the Biological Delivery Systems MyoStar injection and mapping catheters, to stimulate the growth of blood vessels around blocked coronary arteries.”In the company’s words, NCT00117936 on ClinicalTrials.gov
- Other names
- Acidic FGF
Other drugs for Coronary Disease
- XTR004Sinotau Pharmaceutical Group · Phase 3
- EA-230EBI Anti Sepsis BV · Phase 3
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
- ZiltivekimabNovo Nordisk · Phase 3
- RetatrutideEli Lilly · Phase 3
Coming up2
- 15 Nov 2029Phase 2 trial completes · ClinicalTrials.gov
- 5 Feb 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 15 Nov 2029 | Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease | |
| Phase 1/2Not yet recruiting | 5 Feb 2030 | FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease | |
| Phase 1Completed | 2 Sep 2006 | FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026